Coloplast A/S (CLPBY) Expected to Post Quarterly Earnings on Tuesday

Coloplast A/S (OTCMKTS:CLPBY) is expected to release its results before the market opens on Tuesday, August 18th. Analysts expect Coloplast A/S to post earnings of $0.10 per share and revenue of $1.1186 billion for the quarter.

Coloplast A/S (OTCMKTS:CLPBY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a return on equity of 33.15% and a net margin of 7.46%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.11 billion. On average, analysts expect Coloplast A/S to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coloplast A/S Trading Down 2.2%

Shares of CLPBY opened at $6.65 on Tuesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.09 and a current ratio of 1.75. The company’s fifty day moving average is $6.16 and its 200 day moving average is $6.74. The stock has a market capitalization of $14.99 billion, a PE ratio of 47.50, a P/E/G ratio of 2.15 and a beta of 0.13. Coloplast A/S has a fifty-two week low of $5.64 and a fifty-two week high of $10.03.

Analyst Ratings Changes

Separately, Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Coloplast A/S presently has a consensus rating of “Hold”.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.